JAZZ

#795
Jazz Pharmaceuticals, Inc.
201.0600 USD
+2.94%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
201.0600
201.0600
년간 변동
128.8000
201.0600
일일 변동
+2.94%
월간 변동
+11.87%
6달 변화
+43.61%
년간 변동율
+43.61%
이전 종가
195.3100
Open
201.0600
Bid
Ask
Low
201.0600
High
201.0600
양
68
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 12.3773 B
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-29.11
Price to sales ratio
2.43

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

뉴스